Member Info for bbrq648

Casper786,
Pivot - 1st Resistance @ around 70.3p
This will be broken soon, and
Pivot - 2nd Resistance @ around 74.6p
Likely chance to be broken late afternoon.
Expectation:
Pivot - 3rd Resistance @ around 79.2p.

Go for the kill, and if we broke all three pivots, then we will break last high of 138.6p with the result of RNS.

bbrq648

Paraytec and University of Sheffield Team under the supervision of Prof. Carl Smythe have made minor modifications during the clinical trials to meet the the MHRA specification.

Thus, we will succeed and comply and exceeds all the requirements stated in the MHRA specification.

RNS is going to be definitely positive.
No going back.

bbrq648

ncar16,
DYOR, and invest.
However, the RNSs expected are going to give positive news.
This investment are for LTH and genuine investors.

bbrq648

Prof. Carl Smythe wrote in the Twitter as follows:
1. Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.

This means that our BRH test can identify low viral loads, which would be found in asymptomatics and pre-symptomatic people.
Notes:
a) It is obviously easy to identify symptomatic people whom will have high viral loads.
b) To stop spreading of the viruses, it is important to identify asymptomatics and pre-symptomatic people and isolate them.
c) This work was not only important and procedurally adopted by BRH.
d) The issue of LFT Test Sensitivity was identified and rectified in BRH test by clearly identifying false positives and false negatives cases, and minimising and increasingly the accuracy of BRH tests.

A small hints were given in BRH RNS dated 01 & 26-Mar-2021, but was not captured by several investors and media, and traders and institutional investors.
Hold on to this shares and avoid selling prematurely without knowing the full capabilities of BRH testing.

Hope this will give some insight for holding or buying shares in BRH/ Paraytec.
Paraytec is 100% owned by BRH, and are in the current Clinical Validation, and development headed by Prof Carl Smythe and his University of Sheffield Team.

bbrq648

Today is the last day that you can buy BRH share under 70p.
Several sellers are going to regret selling their shares in today.
It is always wise to hold till the receipt of RNS, which is knowingly going to be positive, and detailed.
All genuine and LTH are holding but some new holders selling without doing their DYOR.

Good Luck to all and the longer one hold gets the better the price and profit.
Be warned that RNS can land any time today or tomorrow or next week prior to 30-Apr-2021.

bbrq648

Rocky500,
In brief simplistic post.
Several RNSs expected before end of April 2021.
Only seven (7) business days left.

Good Luck to all LTH.
bbrq648

DaProphet Filtered Today.

bbrq648

DaProphet,
I don’t post like you in AVCT, ODX etc.
Only in BRH.
No one have authority except LSE, so just do post what is required and don’t manipulate in this BB.
You have been going on and on with unrelated post and thus filtered.

bbrq648

star786,
I didn’t say that. Are you belong this group?
You are filtered.
bbrq648

DaProphet,
DYOR, but don’t post your research in this BRH BB.
We didn’t ask for your assistance for help. Be a normal investor and observe the BB, take the important points if needed.
Don’t postulate where I am from?

Only derampers/ investors in other competitors fishing and probing/ investors commenting about other shares in this BB/ raise rumours and make comparisons here.
The genuine and LTH doesn’t want these sort of details copying other RNS and posting in this board.

bbrq648

DaProphet,
Our CEO will take care of all the details in a series of RNSs.
Don’t try to teach a master what to do, and don’t compare with our competitors.
As stated in our last RNS dated 26-Mar-2021, wait till end of April 2021.
Until then, please keep calm and steady.
Be positive, and longer the wait, better the Clinical Validation and obtaining CE and other trademarks. The necessary JV/ Manufacturers/ Sales and Logistics agreements will be forthcoming soon.

bbrq648

DaProphet,
Don’t be so smart, a wait with patience for several detailed BRH Live RNS to be posted here.
Are you going nuts? Who is going to publish Contracts, which are confidential agreement between two parties or more.

bbrq648

PrivateRyan,
Have you seen the last two buys?
Why waste time in this BRH BB?
Go and post in some other BB to spread rumours and find faults with BB posts.
Posters give their understanding, and one have to DYOR, prior to investing.
If you want to invest, DYOY and invest, else the opportunity is open elsewhere.

bbrq648

Please see the details of the path:
https://www.msn.com/en-gb/health/medical/reports-of-infected-people-who-had-a-vaccine-dose/ar-BB1fHwIv?li=BBoPWjQ

bbrq648

Yes, one week to go before the receipt of the new RNS regarding the Clinical Validation/ Progress, and JV/ Manufacturers details, etc.

bbrq648

The reasons for the sale by BRH CEO Trevor Brown can fall into one or more categories as outlined below:
1) To pay tax on dividends & profits;
2) To split his investment to several companies to make quick profits;
3) To keep additional funding made available for their future share options;
4) To reinvest back in BRH if time line permits;
5) Not to sell BRH to buyers (dilution of his shares would not make sense);
6) To keep all the IP, trade mark and first manufacturing to production and sales (which will takes another 6 months);
7) Get necessary regulatory approval from MHRA, and trade marks and sell to bidders, rather than taking the product to global market and then sell at better value for Paraytec COVID-19 Test production only;
8) Go for JV/ Manufacturers and licensees to production worldwide and keep within the BRH Umbrella for long term shareholders benefits; and
9) Keep Paraytec within BRH (i.e., 100%) and go for the Alzheimer, Sepsis and other types of viruses test developments for the future shareholders benefits.

Thus, knowing there are nine(9) possibilities available, I wouldn’t want to recommend and expect the same from any other new shareholders/ derampers/ traders or RMS, AVCT or NCYT shareholders to hypothetically make critical comments in this BB about our CEO Trevor Brown.

I would also humbly state that other additional options/ opportunities available, which I will leave BRH BOD to decide, if needed.

Good Luck to all Genuine Shareholders for a blue week from tomorrow,
bbrq648

In addition to my last post, one would have to note that during Clinical Trials, we have resolved the false positives and false negatives.
Furthermore, this is yet to be resolved by our competitors.
Also, we could carry out 1000 matrix testing in within an hour, as per Prof. Carl Smythe.
The Alzheimer’s and Sepsis Testing in progress will help long-standing BRH share value to move northwards.

Hence rest assured that Trevor Brown will not sell shares any more till obtaining successful validation approval and UKCA, CE, FDA trade mark approval and JV/ Manufacturers.

bbrq648

DaProphet,
I am aware of this.
You read my post. Clinical Trials is Clinical Evaluations.
Any the Clinical Validation is going smoothly for BRH/Paraytec in comparison to our competitors.
This is because our BRH/ Paraytec Testing is the best and accurate and fast meeting the MHRA specification.
Hence there won’t be any further delay and as planned approved before end of April 2021.

bbrq648

Kainos,
You are Filtered.
Waste of time - Police not needed, your stupid responses, and discussing other shares in here.
Spreading rumours, and LSE to consider the ban.

bbrq648

BRH/ PARAYTEC are managed well, with the support of Prof. Carl Smythe and his University of Sheffield Team.
All have executed their Work Packages as planned, with the exception of a month during the 2nd lockdown where Sheffield Hospital was busy to collect the samples required for Clinical Test and Validation.
As per the BRH RNS dated 01 & 26- Mar-2021, BRH Test had exceeded expectations, and stated clearly by our CEO Trevor Brown & commendation to Prof. Carl Smythe and his team.
All ducks are in one row, and validation progress was very good with no hindrance.
Only maximum two weeks to receive several RNS with lots of positive news and steady increase in share value.

bbrq648